Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.46 |
| ▸ | LIPE | Q05469 | 6/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.39 |
| ▸ | XPO1 | O14980 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427271 | 0.88 | LIPE (0.58) | LIPEACHEXPO1MGLLKMT2A | |
| SCHEMBL427521 | 0.86 | ACHE (0.47) | LIPEACHEBCHEMAPTMGLL | |
| SCHEMBL426706 | 0.77 | GPBAR1 (0.46) | GPBAR1LIPEACHETP53LTC4S | |
| SCHEMBL424347 | 0.73 | LIPE (0.56) | LIPEACHEBCHEMGLLKMT2A | |
| SCHEMBL427525 | 0.71 | PIK3C3 (0.38) | HDAC1HDAC6MAPTMGLL | |
| SCHEMBL9894487 | 0.71 | HDAC1 (0.46) | HDAC1HDAC6MAPTMGLLKMT2A | |
| SCHEMBL425582 | 0.69 | PARP10 (0.47) | LIPEACHEMGLLKMT2A | |
| SCHEMBL31301304 | 0.68 | GPBAR1 (0.46) | GPBAR1TP53MAPTKMT2A | |
| SCHEMBL2179538 | 0.67 | BCHE (0.48) | LIPEACHEBCHEHDAC1HDAC6 | |
| SCHEMBL6769817 | 0.66 | GPBAR1 (0.46) | GPBAR1LIPEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | GPBAR1 218/4885LIPE 61/4885ACHE 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.